Loading clinical trials...
Loading clinical trials...
Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions
Interventions
Welgenaleucel
Locations
1
Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Start Date
July 27, 2020
Primary Completion Date
June 30, 2021
Completion Date
December 31, 2021
Last Updated
January 22, 2021
NCT06189391
NCT05755087
NCT07123454
NCT06230224
NCT06242834
NCT05098613
Lead Sponsor
UWELL Biopharma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions